GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnax Lab Ltd (BOM:506128) » Definitions » Cyclically Adjusted PS Ratio

Parnax Lab (BOM:506128) Cyclically Adjusted PS Ratio : 0.66 (As of Jun. 23, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Parnax Lab Cyclically Adjusted PS Ratio?

As of today (2024-06-23), Parnax Lab's current share price is ₹107.63. Parnax Lab's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₹162.96. Parnax Lab's Cyclically Adjusted PS Ratio for today is 0.66.

The historical rank and industry rank for Parnax Lab's Cyclically Adjusted PS Ratio or its related term are showing as below:

BOM:506128' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.15   Med: 0.51   Max: 1.11
Current: 0.66

During the past years, Parnax Lab's highest Cyclically Adjusted PS Ratio was 1.11. The lowest was 0.15. And the median was 0.51.

BOM:506128's Cyclically Adjusted PS Ratio is ranked better than
79.54% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs BOM:506128: 0.66

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Parnax Lab's adjusted revenue per share data for the three months ended in Mar. 2024 was ₹40.353. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹162.96 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Parnax Lab Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Parnax Lab's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnax Lab Cyclically Adjusted PS Ratio Chart

Parnax Lab Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.15 0.93 0.34 0.79

Parnax Lab Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.37 0.55 0.54 0.79

Competitive Comparison of Parnax Lab's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Parnax Lab's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parnax Lab's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnax Lab's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Parnax Lab's Cyclically Adjusted PS Ratio falls into.



Parnax Lab Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Parnax Lab's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=107.63/162.96
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parnax Lab's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Parnax Lab's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=40.353/153.0345*153.0345
=40.353

Current CPI (Mar. 2024) = 153.0345.

Parnax Lab Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 24.888 94.103 40.474
201409 31.684 96.780 50.100
201412 33.778 96.780 53.412
201503 30.621 97.163 48.229
201506 19.093 99.841 29.266
201509 21.942 101.753 33.000
201512 20.430 102.901 30.384
201603 22.205 102.518 33.147
201606 25.542 105.961 36.889
201609 29.546 105.961 42.672
201612 31.373 105.196 45.640
201703 25.109 105.196 36.527
201706 26.925 107.109 38.470
201709 41.865 109.021 58.766
201712 29.555 109.404 41.342
201803 25.222 109.786 35.158
201806 27.269 111.317 37.489
201809 49.757 115.142 66.132
201812 27.618 115.142 36.707
201903 23.515 118.202 30.445
201906 25.545 120.880 32.340
201909 30.222 123.175 37.548
201912 30.008 126.235 36.379
202003 27.761 124.705 34.067
202006 20.401 127.000 24.583
202009 31.496 130.118 37.043
202012 29.190 130.889 34.129
202103 24.717 131.771 28.706
202106 33.862 134.084 38.648
202109 42.120 135.847 47.449
202112 59.787 138.161 66.223
202203 55.822 138.822 61.537
202206 37.512 142.347 40.328
202209 37.610 144.661 39.787
202212 43.985 145.763 46.179
202303 33.293 146.865 34.692
202306 42.547 150.280 43.327
202309 37.160 151.492 37.538
202312 44.512 152.924 44.544
202403 40.353 153.035 40.353

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Parnax Lab  (BOM:506128) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Parnax Lab Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Parnax Lab's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnax Lab (BOM:506128) Business Description

Traded in Other Exchanges
N/A
Address
104 - 107, Building No. 8, Gala No. 114, Jogani Industrial Complex, Panchsheel Nagar, Next to Modi Hyundai Service Centre, Chunabhatti, Sion, Mumbai, MH, IND, 400 022
Parnax Lab Ltd is principally engaged in the manufacturing and export of Pharmaceutical Formulations. Its product categories include Pharmaceuticals; Cosmetics; Herbal and Nutraceuticals. The company is developing and delivering Oral Formulations such as Cough Expectorants, Antacids, Anti-Histamines, Multi-Vitamins, Enzyme Preparations, Pediatric Formulations, Special Formulations for Geriatrics, Highly Viscous Products, Suspensions, and others.

Parnax Lab (BOM:506128) Headlines

No Headlines